We may only be two months into 2025, but Alltrna CEO Michelle Werner sees many reasons for ๐ต๐ผ๐ฝ๐ฒ in rare diseases this year and beyond. Much of that hope comes from rapid advancements in technology and new treatment modalities, from gene editing and gene therapy to new #tRNA medicines.
What will it take for novel therapies to enter the clinic?
Michelle tells @m_mcphill of @axiomhcs, it takes an environment that supports innovation, with incentives, novel clinical trial designs, and other enabling regulations โ and she urges the rare disease community to continue to push for these things.
๐๏ธListen to the full interview on Spotify: https://t.co/cHoir0JKR4
#RareAware #RareDiseaseWeek #RareDiseaseDay #RareDiseaseDay2025 #VoicesOfCare #RareDiseases #PatientCare #Collaboration #Advocacy #Research #AxiomThinkTank #AxiomREACH
๐ Partnering for Innovation โ A thought-provoking discussion led by Paul Biondi of Flagship Pioneering at the Axiom Crossroads Summit.
Catch the full conversation here: https://t.co/Un0kQmIqZ2
#HealthcareInnovation#Collaboration#AxiomSummit#AxiomThinkTank
Get ready for an insightful session at the Axiom Crossroads Summit, led by Biren Amin, Managing Director of @Piper_Sandler , on the Outlook on Capital Markets. Discover key trends and strategies that are shaping the investment landscape in healthcare.
https://t.co/SuIb1Dr7rg
Thrilled to share that @PaulBiondi9 , General Partner of @FlagshipPioneer and President of Pioneering Medicine will be leading an insightful discussion at the Axiom Crossroads Summit in Boston next week!
Register here: https://t.co/SuIb1Dr7rg
Donโt miss out on this chance to deepen your understanding and engage with top minds in oncology. Secure your spot now - registration is required!
๐ REGISTER HERE for Post #ESMO2024 Townhall at
https://t.co/D5YpRwe9U6
Women at Axiom drive innovation with unique perspectives, leadership, and collaboration. Their impact bridges past achievements to future aspirations, embodying empowerment and inclusion.
#InspireInclusion#AxiomThinkTank#IWD#InternationalWomensDay
From now through #GivingTuesday, we're highlighting some of the NJ nonprofits that could benefit from your support, as featured in our 2023 Giving Guide ๐ Click through to learn more about the @AxiomREACH Foundation: https://t.co/mRCXFwm7WK
Join us at ESMO 2023 booth #753 for a chance to meet the Axiom Thinkers, gain invaluable Oncology insights, one-on-one sessions with luminaries, and explore strategic partnerships. We look forward to seeing you at ESMO 2023!
Madrid, Spain
20โ24 October 2023
#ESMO23#ThinkTank
We are excited to announce publication of our first Axiom Assessment is now available for purchase. This analysis reviews key trends and players in the ADC, antibody, and T cell engager oncology pipeline. Come check it out!
Purchase an Axiom Assessment:
https://t.co/eboWyx3ztw
Axiom U's first week was inspiring, gathering of brilliant minds, dedicated to fostering innovation, intellectual curiosity, and meaningful connections at the esteemed #AxiomTable#AxiomLife#AxiomThinkTank#AxiomU
The Axiom thinkers send our congratulations to @Sarepta Therapeutics on the FDA's approval of their groundbreaking gene therapy for Duchenne Muscular Dystrophy. While there is still a long way to go, we celebrate each step forward on this journey. Keep pushing boundaries!
Join us for an inspiring gathering of top-notch experts from prestigious academic centers and visionary leaders from the biopharma industry. Together, we will engage in powerful discussions that explore the ever-evolving landscape of cancer care & work toward bridging disparities
Antibody drug conjugates are one of the most exciting areas in oncology today, but the mechanisms of resistance are varied and complex. How might resistance to an ADC impact a patientโs future therapeutic options?
#AxiomThinkTank#therapeutic#oncology
2022 saw advances in use of targeted and IO therapies for GI cancers. Check out Axiom's latest white paper to learn more about the readout of pivotal clinical trials, and nuances in treatment of gastric and pancreatic cancers.
Read here:
https://t.co/Y6SugysLkn #oncology#Cancer
Axiomโs latest white paper reviewing 2022 advances in GU cancers here:
https://t.co/9W9hvyLENO
We are eagerly awaiting key trial results for new approaches in 2023. #AxiomThinkTank
Axiom continues to thrive and grow into 2023. We recently held an open house to showcase the Think Tank for prospective candidates. We are continuing to hire - Life Science Specialist candidates are encouraged to apply at https://t.co/GMG1BTkv1t
#hiringnow#lifescience#openhouse